Oscar Health's Investor Day TAM Expansion Meets a Cautious Risk-Adjustment Reality

What happened

Oscar Health hosted an investor day where management raised 2026 operating earnings guidance to $600-800M and projected 2029 EPS above $4, driven by ACA execution and new CHOICE and Lucie marketplace offerings. Seeking Alpha upgraded the stock to Strong Buy with a $45 fair value, citing a 65% expansion in addressable market and revenue estimates rising from $18.85B in 2026 to $32.6B in 2029. However, the latest DeepValue master report maintained a more cautious POTENTIAL SELL rating at $20.9, pointing to a net risk-adjustment payable of $3.97B after a +$1.44B Q1 build and an expected MLR normalization from 70.5% to 82.4-83.4%. The bullish investor day narrative assumes flawless execution on new product lines while the existing balance sheet shows rising regulatory transfer obligations and membership declines after enhanced subsidies expired. No new data in the article addresses the observable risk-adjustment accrual (~24% of direct premiums vs ~20% full-year expectation) or confirms that Q1 profitability reflects a stable run-rate rather than one-time favorable reserve development.

Implication

The Strong Buy upgrade and $45 fair value rely on management hitting 2026-2029 targets across new product lines (CHOICE, Lucie) that have no demonstrated earnings history in filings, so current valuation already prices in substantial success. Until quarterly evidence shows risk-adjustment accrual trending toward ≤21% of direct premiums and net payable stabilizing near $4.0B, the balance-sheet swing factor continues to dominate near-term equity risk. Q1 2026's 70.5% MLR benefited from $68M favorable prior-period reserve development; full-year guidance of 82.4-83.4% implies significant deterioration that could erode earnings if medical trend overshoots. Membership declines after enhanced APTC expiration add another layer of uncertainty to revenue and SG&A leverage, making the investor day TAM expansion feel more like a long-dated call option than a current valuation anchor. Position sizing should reflect that the stock can re-rate lower on observable risk-adjustment and MLR normalization even with adequate liquidity, so we maintain a POTENTIAL SELL stance with an attractive entry near $16 and trim above $27.

Thesis delta

The investor day introduces a larger long-horizon TAM via CHOICE and Lucie, but does not alter our near-term risk framework. Our prior thesis centered on a POTENTIAL SELL at $20.9 due to risk-adjustment payable build and expected MLR normalization, and those factors remain unresolved. Therefore the thesis shifts only marginally: we acknowledge optionality from new market expansions, but maintain a cautious stance until Q2-Q3 evidence confirms risk-adjustment accrual ≤21% and net payable stability.